Less than a tenth of patients who could benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it releases its inaugural advice on the drugs.
With in excess of 1,000,000,000 individuals worldwide now obese, it is calling for more widespread and fairer access to these injectable treatments.
According to estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 without intervention.
"The new guidance acknowledges that excess weight is a lifelong illness that can be addressed with comprehensive and ongoing care," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are significant hurdles to widespread availability to the jabs that can assist patients in reducing substantial weight, says the body.
GLP-1 Therapy Supply Crisis
Even under the present best projected scenario, the supply of GLP-1 therapies could only cover approximately 100 million people – under 10% of the global need, according to the WHO.
The advice encourages governments and firms to increase access, by strategies like licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of a leading brand – is due to expire in a number of countries in 2026.
The Way Obesity Injections Operate
These medications imitate a biological compound to reduce digestion speed, suppress the appetite and boost feelings of fullness so people reduce food intake.
Individuals usually begin shedding pounds within a few weeks of beginning the regular doses.
Research suggests users may put most of the weight back on a year later of halting the drug, as their normal food cravings return.
To be overweight or obese increases your likelihood for contracting medical conditions, including diabetes, heart disease, brain attack, and certain cancers.
Excess weight affects people in all nations and was linked to over three and a half million deaths worldwide in 2024, according to the WHO.
